The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
Abstract
PURPOSE: To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs. PATIENTS AND METHODS: Patient leukocyte and neutrophil data after administration of docetaxel, paclitaxel, and etoposide were used to develop the model, which was also applied to myelosuppression data from 2′-deoxy-2′-methylidenecytidine (DMDC), irinotecan (CPT-11), and vinflunine administrations. The model consisted of a proliferating compartment that was sensitive to drugs, three transit compartments that represented maturation, and a compartment of circulating blood cells. Three system-related parameters were estimated: baseline, mean transit time, and a feedback parameter. Drug concentration-time profiles affected the proliferation of sensitive cells by either an inhibitory linear model or an inhibitory E max model. To evaluate the model, system-related parameters were fixed to the same values for all drugs, which were based on the results from the estimations, and only drug-specific parameters were estimated. All modeling was performed using NONMEM software. RESULTS: For all investigated drugs, the model successfully described myelosuppression. Consecutive courses and different schedules of administration were also well characterized. Similar system-related parameter estimates were obtained for the different drugs and also for leukocytes compared with neutrophils. In addition, when system-related parameters were fixed, the model well characterized chemotherapy-induced myelosuppression for the different drugs. CONCLUSION: This model predicted myelosuppression after administration of one of several different chemotherapeutic drugs. In addition, with fixed system-related parameters to proposed values, and only drug-related parameters estimated, myelosuppression can be predicted. We propose that this model can be a useful tool in the development of anticancer drugs and therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
Jonsson, E. N., & Karlsson, M. O. (1998) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(98)00067-4 · Cited by 1,002
Self-citationKawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Dancey, J. T., Deubelbeiss, K. A., Harker, L. A., & Finch, C. A. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108517 · Cited by 573
The importance of modeling interoccasion variability in population pharmacokinetic analyses
Karlsson, M. O., & Sheiner, L. B. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01113502 · Cited by 485
Self-citationBruno, R., Hille, D., Riva, A., Vivier, N., ten Bokkel Huinnink, W. W., van Oosterom, A. T., Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V, et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.187 · Cited by 423
Analytical Review: The Kinetics of Granulopoiesis in Normal Man
CARTWRIGHT, G. E., ATHENS, J. W., & WINTROBE, M. M. (1964) · Blood · doi:10.1182/blood.v24.6.780.780 · Cited by 391
Assessment of Actual Significance Levels for Covariate Effects in NONMEM
Wählby, U., Jonsson, E. N., & Karlsson, M. O. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1011527125570 · Cited by 292
Self-citationA population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation
Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G., & Sheiner, L. B. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353487 · Cited by 265
The Clinical Pharmacology of Etoposide and Teniposide
Clark, P. I., & Slevin, M. L. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198712040-00001 · Cited by 263
Cited by
Mould, D., & Upton, R. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.14 · Cited by 897
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Savic, R. M., & Karlsson, M. O. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9133-0 · Cited by 636
Self-citationPharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
Diao, L., & Meibohm, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0079-0 · Cited by 369
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Self-citationLahoz-Beneytez, J., Elemans, M., Zhang, Y., Ahmed, R., Salam, A., Block, M., Niederalt, C., Asquith, B., & Macallan, D. (2016) · Blood · doi:10.1182/blood-2016-03-700336 · Cited by 293
Ribonucleotide Reductase Inhibitors and Future Drug Design
Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723949 · Cited by 284
Upton, R., & Mould, D. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.71 · Cited by 265
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Kaefer, A., Yang, J., Noertersheuser, P., Mensing, S., Humerickhouse, R., Awni, W., & Xiong, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2530-9 · Cited by 161
Ribba, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1094281 · Cited by 24
Shankaran, H., Cronin, A., Barnes, J., Sharma, P., Tolsma, J., Jasper, P., & Mettetal, J. T. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12255 · Cited by 20
Gao, W., Liu, J., Musante, C. J., Zhu, H., Thompson, M., Shah, M., Cao, Y., Ivaturi, V., Conaway, M. R., Bottino, D., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3725 · Cited by 2
Metadata
- Authors
- Friberg, L. E., Henningsson, A., Maas, H., Nguyen, L., & Karlsson, M. O.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-12-15
- Volume
- 20
- Issue
- 24
- Pages
- 4713-4721
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2082535104
- Cited by
- 534
- References
- 24
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.